Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05385978

A Study of Distal Jejunal-release Dextrose in Obese Participants

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Obese Body Weight Cardiovascular Diseases Digestive System Diseases Endocrine System Diseases Fatty Liver Hypertension Liver Diseases Non-alcoholic Fatty Liver Disease Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

LTD "Acad. G. Chapidze Emergency Cardiology Center", Tbilisi, Georgia

Loading trial locations.

About this study

This is a randomized, double-blind, placebo-controlled, parallel-group, phase II proof-of-concept study to be conducted in 150 adult obese male and female participants who are 18 to 70 years of age with or without one or more endocrine and/or metabolic conditions. The study aims to evaluate the efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese participants.

Participants will be randomly assigned to receive either APHD-012 (distal jejunal-release dextrose or APH-012P (a matching placebo). There will be two cohorts in the study. Participants from Cohort 1 will receive study medication once daily for 12 months (360 days), and participants from Cohort 2 will receive study medication once daily for 6 months (180 days).

Overall, 150 participants will be enrolled in the study:

  • Cohort 1 (60 participants) - 6-month treatment period + 6-month maintenance treatment period
  • Cohort 2 (90 participants) - 6-month treatment period

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index 30.0-39.9 kg/m^2 and/or waist circumference: men >102 cm, women >88 cm
  • Stable body weight: gain or loss in body weight ≤5 kg over last 3 months
  • Obese participants with or without one or more of the following conditions:
  • NAFLD - simple steatosis based on a FibroScan CAP™ test result at screening (CAP Score ≥238 decibel-milliwatts (dB/m) (Steatosis Grades 1-3) with no or mild fibrosis (F0-F1 fibrosis Score)
  • NASH - steatohepatitis based on FibroScan fibrosis Score at screening (≥7.5 kPa and <14 kPa (Stage F2-F3)
  • Confirmed medical history of metabolic syndrome
  • Homeostatic Model Assessment of Insulin Resistance (HOMA IR) Score ≥2
  • Confirmed medical history of type 2 diabetes mellitus (T2DM) diagnosis or HbA1c ≥7.0 and <11 (based on screening values)
  • High total cholesterol ≥240 mg/dL (based on screening values)
  • Hypertension (participants with Stage 1 hypertension (systolic blood pressure [SBP] ≥130 mmHg <180 mmHg, diastolic blood pressure [DBP] ≥80 mmHg <110 mmHg) (based on screening values)
  • If on medication to manage endocrine/metabolic conditions, must be on stable doses of medication ≥3 months prior to screening:
  • Participants with T2DM may be treated with either diet and exercise alone, metformin, sulphonylurea, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and bromocriptine quick-release (QR) as single agents or combination therapy.
  • As lipid-lowering medication participants may be treated with statins and fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, or supplements like omega-3-fatty acids.
  • As antihypertensive medication participants may be treated with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-inhibitors, diuretics, or calcium channel blockers.
  • Normal GI function, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study

Exclusion criteria

  • Incomplete Coronavirus Disease of 2019 (COVID-19) vaccination
  • Treatment with weight loss medications in the past 3 months
  • Proven history of bulimia or anorexia nervosa
  • Treatment with injectable antidiabetic medications in the last 3 months (e.g. Glucagon-like peptide-1 [GLP-1] receptor agonists, insulin)
  • Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months
  • NASH with cirrhosis (fibrosis Score=F4 (≥14 kPa) as determined by screening FibroScan
  • Confirmed medical history of liver cirrhosis, cholestatic disease, alcohol-related liver disease
  • Type 1 diabetes mellitus, HbA1c ≥11, fasting plasma glucose levels ≥270 mg/dL
  • Proliferative retinopathy or maculopathy
  • Abnormal liver function tests:
  • Transaminases:
  • Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥5 x upper limit of normal (ULN) for participants with NAFLD or NASH (as determined by screening FibroScan)
  • ALT/AST ≥2.5 x ULN for participants without NAFLD or NASH (as determined by screening FibroScan)
  • Alkaline phosphatase (ALK) ≥2.5 x ULN
  • Total bilirubin ≥2 x ULN
  • Stage 4 hypertension (SBP ≥180, DBP ≥110)
  • History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematologic, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator does not consider a disqualification for participation in the study

Treatment and study plan

APHD-012

Drug

Distal jejunal-release dextrose beads (Aphaia technology, AT)

Other names: Distal jejunal-release dextrose beads

APHD-012P

Drug

Distal jejunal-release placebo beads

Other names: Placebo

Primary outcomes

  1. Changes from Baseline in Percent Weight Change Compared with Placebo

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Bodyweight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

Secondary outcomes

  1. Percentage of Participants with ≥2.5% Baseline Body Weight Loss at 6 Months Compared with Placebo (Weight Loss Responders)

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  2. Percentage of Participants with ≥5% Baseline Body Weight Loss at 6 Months Compared with Placebo (Weight Loss Responders)

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  3. The Difference in Mean Absolute Weight Loss Compared with Placebo at 6 Months

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  4. Mean Absolute Change and Percent Change of Waist Circumference

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Waist circumference measurements will be done using a standard measuring tape referring to centimeter Scale.

  5. Mean Absolute Change and Percent Change of Systolic Blood Pressure and Diastolic Blood Pressure

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured using a standard sphygmomanometer with the Riva-Rocci cuff and a stethoscope; alternatively, an automatic device with upper arm cuff can be used. Measurements are done in sitting position after 5 minutes of rest.

  6. Mean Absolute Change and Percent Change of Heart Rate

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Heart rate measurement will be obtained along with the blood pressure measurement.

  7. Mean Absolute Change and Percent Change of Triglycerides and Cholesterol

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Triglycerides and cholesterol (including total cholesterol, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) will be measured using standard clinical laboratory methods at the site laboratories.

  8. Mean Absolute Change and Percent Change of Homeostatic Model Assessment of Insulin Resistance

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Homeostasis model assessment-estimated insulin resistance (HOMA-IR) will be determined with standard clinical laboratory methods.

  9. Mean Absolute Change and Percent Change of Fasting Plasma Glucose, Fasting Plasma Insulin and Glycated Hemoglobin

    Time frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1

    Fasting plasma glucose will be determined using a standard blood glucometer. Fasting plasma insulin will be determined with standard clinical laboratory methods. Glycated hemoglobin (HbA1c) will be measured using a standard enzyme-linked immunoassay (ELISA) method.

    HbA1c will be measured in participants with type two diabetes (T2DM).

  10. Mean Absolute Change and Percent Change of Alanine Transaminase, Aspartate Transaminase and Gamma Glutamyl Transpeptidase

    Time frame: At Baseline and at Day 90, at Day 180 for Cohort 2 and at Day 360 for Cohort 1

    Liver enzymes (ALT, AST, GGT) will be measured using standard clinical laboratory methods.

  11. Mean Absolute Change and Percent Change of Fatty Liver Controlled Attenuation Parameter Score and Liver Fibrosis Score

    Time frame: At Baseline and at Day 90, at Day 180 for Cohort 2 and at Day 360 for Cohort 1

    Fatty liver Controlled Attenuation Parameter (CAP) Score will be measured in:

    • Participants with Non-alcoholic fatty liver disease (NAFLD): Steatosis grade and;
    • Participants with Non-alcoholic steatohepatitis (NASH): fibrosis Score category

    Fatty liver CAP Score and liver fibrosis Score will be measured using FibroScan™ equipment or equivalent.

  12. Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE)

    Time frame: At each visit until Day 180 for Cohort 2 and until Day 360 for Cohort 1

    A treatment-emergent adverse event is defined as any event not present prior to the initiation of the drug treatment or any event already present that worsens in either intensity or frequency following exposure to the drug treatment

  13. Advance Understanding of Dose/Exposure - Response Relationships

    Time frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1

    Dose/Exposure - Response Relationships will be evaluated.

Other outcomes

  1. Glucagon-like Peptide-1 Level Determination

    Time frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1

    Blood samples of 2 mL will be taken at pre-dose (-0.5 h [within 5 minutes]) and 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 and 8.0 hours after investigational medicinal product administration.

    The blood samples for the determination of Glucagon-like peptide-1 (GLP-1) and circulating biomarkers and micro Ribonucleic acid (miRNA)1983 will be collected in BD P800 tubes.

  2. Area Under the Plasma Concentration-time Curve from Time 0 to 8 Hours (AUC0-8)

    Time frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1

  3. Maximum Plasma Concentration (Cmax)

    Time frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1

  4. Time to Reach the Maximum Plasma Concentration (Tmax)

    Time frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1

Sponsors and collaborators

Lead sponsor

Aphaia Pharma US LLC

Industry

Registry information

Official study title

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 23, 2022
Registry last updated
Oct 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.